Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy

Ramiro Vázquez (1) , Maria E Riveiro (2) , Caroline Berenguer-Daize (3) , Anthony O’kane (4) , Julie Gormley (4) , Olivier Touzelet (4) , Keyvan Rezai (5) , Mohamed Bekradda (2) , L'Houcine Ouafik (3, 6)

1 IIT - Istituto Italiano di Tecnologia
2 E2DG - Early Drug Development Group
3 INP - Institut de neurophysiopathologie
4 FusionAntibodies
5 Département de radio-pharmacologie
6 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]

tumor angiogenesis, metastasis and growth following treatment with AM-neutralizing antibodies, AM receptor antagonists, or AM receptor interference. Anti-AM therapy is a promising strategy to be explored in oncology, not only as an anti-angiogenic alternative in the context of acquired resistance to VEGF treatment, but also as a potential antimetastatic approach.

Keywords: adrenomedullin; angiogenesis; cancer; metastasis; AM 1 and AM 2; RAMP1-3

Domains: Life Sciences [q-bio]; Cancer

Ramiro Vázquez, Maria E Riveiro, Caroline Berenguer-Daize, Anthony O’kane, Julie Gormley, et al.. Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy. Frontiers in Oncology, 2021, 10, ⟨10.3389/fonc.2020.589218⟩. ⟨hal-03105775⟩